People
Michael Wacker
Michael Wacker joined Biomed in 2019 and is currently listed as managing partner with both BioMedPartners and BiomedVC. He co-founded vaccine developer GlycoVaxyn, later acquired by GSK, and previously held leadership roles at Polyneuron and Inositec. His training includes biochemistry and microbiology at ETH Zurich. These are institutional manager affiliations; no personal portfolio investment is inferred.
Roles
Topas Therapeutics
CurrentSupervisory Board Member
BioMedPartners
CurrentManaging Partner
BiomedVC
CurrentManaging Partner
BioMedPartners
CurrentStatutory Board Director (2021 official appointment confirmation)
BiomedVC
CurrentChair, statutory board (2023 official appointment confirmation)